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During the past two decades, major advances in the treat-
ment of acute ST-segment elevation myocardial infarction
(STEMI), including coronary care units and thrombolysis,
have lowered the mortality after hospital presentation to
approximately 5%. However, in recent years, there has been
little further improvement in survival (1). Neither newer
fibrinolytic agents nor attempts to combine a reduced-dose
fibrinolytic agent with a glycoprotein (GP) IIb/IIIa inhibi-
tor, which increase 60- to 90-min infarct-artery–related
patency, have resulted in improved survival (2–4). Reasons
for this apparent paradox may include poor myocardial
perfusion through the microvasculature despite optimal
epicardial coronary artery flow, continued myocardial cell
death in ischemic border zones, or an inability to impact the
high mortality associated with cardiogenic shock.
See page 1348
THE PRESENT STUDY
In this issue of the Journal, the TETAMI investigators (5)
highlight another group of high-risk STEMI patients,
namely those ineligible for reperfusion by either thrombol-
ysis or primary percutaneous coronary intervention (PCI).
Most were not treated conventionally because of either late
presentation 12 h after symptom onset (79%) or no
ST-segment elevation on admission (9%) (5). In this study,
1,224 patients were randomized to one of four treatment
groups, enoxaparin versus unfractionated heparin, with or
without the GP IIb/IIIa inhibitor tirofiban. The study failed
to demonstrate a benefit for either enoxaparin or tirofiban
over unfractionated heparin or placebo on the 30-day
composite end point of death, reinfarction, or recurrent
angina, which averaged 16.5%.
The authors are to be congratulated on completing this
well-designed, randomized study in a large number of
high-risk STEMI patients ineligible for standard reperfu-
sion strategies. Unfortunately, their results add to the list of
ineffective therapies for such patients. There were slight
trends toward benefit with enoxaparin on recurrent myocar-
dial infarction and angina, particularly in the least seriously
ill patients, but these results were not statistically significant.
Limitations of the study, as pointed out by the authors,
included a lower-than-expected event rate, thereby reducing
the power of the study to detect an important difference,
and a heterogenous patient population (5). Other limita-
tions included the possibility that the dose of unfractionated
heparin was ineffectual (data on adequacy of anticoagulation
was not provided) or that the dose of tirofiban was too low
(6). Finally, although mortality is the traditional gold
standard end point for myocardial infarction trials, other
end points, such as infarct size, may better reflect the effects
of therapy on long-term survival.
FUTURE THERAPIES FOR STEMI
To further reduce mortality associated with STEMI, new
therapies will be needed to improve patency, myocardial
perfusion, preserve ischemic myocardium, and reduce the
mortality associated with shock. The benefits of reperfusion
are greatest for patients who present early after symptom
onset, emphasizing the need for patient awareness, early
detection, and the potential benefit of administering reper-
fusion therapy in the field (7). The greater use of primary
PCI and transfer strategies that combine pharmacologic and
mechanical reperfusion (“facilitated PCI”) are under evalu-
ation (8–10). Other approaches to increase early patency
include transcutaneous ultrasound to optimize lytic efficacy
(11) and combinations of new antithrombin and antiplatelet
agents (e.g., low molecular weight heparins, direct thrombin
inhibitors, thienopyridines, and a P-selectin antagonist).
In addition to improving infarct-related artery patency,
future strategies will also need to focus on improving
myocardial perfusion through the microvasculature, which
is an independent predictor of outcome (12). The platelet
GP IIb/IIIa inhibitor abciximab improves coronary flow
reserve (13), which may contribute to its benefit during
primary PCI (14). Other approaches to reducing distal
embolization during primary PCI that are under investiga-
tion include thrombectomy (15,16) and distal protection
devices (17,18).
Even with successful reperfusion of both the epicardial
artery and its microvasculature, further myocardial cell death
may occur in adjacent ischemic territory. A number of
treatments to reduce infarct size by preserving myocardial
cell viability are under investigation. The theoretical benefit
of glucose-potassium-insulin infusion first theorized by
Sodi-Pallares in 1962 (19) and confirmed in a modern lytic
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trial (20) is being reassessed in the ongoing CREATE mega
trial. However, many other pharmacologic approaches, in-
cluding adenosine (21), neutrophil inhibition with an anti-
body to the CD 11/18 integrin (22), prostaglandin E-1
inhibition, inhibition of the sodium-hydrogen exchange
pump (23), and complement C5 blockade (24), all have
been unsuccessful. Two mechanical myocardial preservation
strategies that show promise in pilot studies are hyperox-
emic blood perfusion in the infarct-related artery (25) and
systemic hypothermia via an inferior vena cava heat-
exchange catheter (26).
For patients who present with late and large infarctions,
the options are limited, as demonstrated in the TETAMI
trial. Furthermore, the residual viable myocardium may be
insufficient to allow survival. Although a randomized trial
demonstrated that emergent revascularization could im-
prove the survival of patients with shock as compared with
initial medical stabilization, the mortality in both groups
was about 50% at 30 days (27). Ventricular-assist devices
that can be rapidly inserted percutaneously may be beneficial
in selected patients, and one such device is undergoing
randomized assessment (28). Cardiac transplantation and
myocardial regeneration (29) may also offer hope for some
of these patients.
CONCLUSIONS
The advances in STEMI management over the past two
decades have been remarkable. Nonetheless, the pace of
mortality reduction has slowed. Future therapies that ad-
dress the three “Ps” of patency, perfusion, and preservation,
as well as novel therapies for cardiogenic shock, will be
necessary to further improve survival. The benefit of deliv-
ering this specialized care in regional centers of excellence is
obvious; however, the methodology to implement this
approach is not (30,31).
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